BIMANEXT 0.1 MG/ML Krople do oczu, roztwór

Ocena recepty online

Ocena recepty online

Lekarz przeanalizuje Twój przypadek i zdecyduje, czy wystawienie recepty jest medycznie uzasadnione.

Porozmawiaj z lekarzem o tym leku

Porozmawiaj z lekarzem o tym leku

Omów swoje objawy i opcje leczenia podczas szybkiej konsultacji online.

Lekarz
5.0(36)

Andrei Popov

Medycyna ogólnaMedycyna bólu7 lat doświadczenia

Dr Andrei Popov jest lekarzem rodzinnym ze specjalistycznym przygotowaniem w zakresie leczenia bólu przewlekłego. Prowadzi konsultacje wideo dla dorosłych w Hiszpanii i w całej Europie: zarówno jeśli od miesięcy zmagasz się z bólem, którego nikt nie potrafił dobrze wyjaśnić, jak i wtedy, gdy potrzebujesz rozwiązać problem zdrowotny bez czekania tygodniami na wizytę.

Jego podejście jest jasne: wysłuchać, uporządkować Twój przypadek i przedstawić praktyczny plan działania oparty na medycynie opartej na dowodach oraz dostosowany do Twojej historii medycznej i potrzeb.

Ból: w czym może pomóc

  •   Ból przewlekły (ponad 3 miesiące)
  •   Migrena i nawracające lub bardzo silne bóle głowy
  •   Ból szyi, odcinka lędźwiowego, pleców i stawów
  •   Ból pourazowy po urazach lub operacjach
  •   Ból pochodzenia neurologicznego: neuralgia, ból neuropatyczny, fibromialgia

Medycyna ogólna

  •   Częste infekcje dróg oddechowych (przeziębienie, grypa, uporczywy kaszel)
  •   Nadciśnienie, cukrzyca i zaburzenia metaboliczne
  •   Omówienie wyników badań laboratoryjnych oraz raportów MRI/CT (wyjaśnione prostym językiem)
  •   Medycyna profilaktyczna i monitorowanie zdrowia
  •   Druga opinia oraz dostosowanie leczenia (jeśli jest to klinicznie uzasadnione)

Jak wygląda konsultacja
 Każda sesja trwa do 30 minut. Omawiane są objawy, historia choroby, przyjmowane leki oraz dostarczone badania. Na zakończenie otrzymujesz jasny plan leczenia, kolejne kroki oraz wskazówki, kiedy warto zaplanować dalszą kontrolę. Jeśli zostaną wykryte sygnały alarmowe, lekarz jasno poinformuje, czy konieczna jest wizyta osobista lub pilna pomoc medyczna.

Umów wideokonsultację
zł365
Ta strona ma charakter informacyjny. Skonsultuj się z lekarzem, aby uzyskać indywidualną poradę. Jeśli objawy są poważne, zadzwoń pod numer alarmowy.
About the medicine

Jak stosować BIMANEXT

Treść ulotki

  1. BIMANEXT 0,3 mg/ml, eye drops, solution
    1. What is BIMANEXT 0.3 mg/ml and what is it used for
    2. What you need to know before using BIMANEXT 0.3 mg/ml
    3. How to use BIMANEXT 0.3 mg/ml
    4. Possible side effects
    5. How to store 0.3 mg/ml
    6. Package contents and other information
  2. BIMANEXT 0,3 mg/ml, eye drops, solution in single-dose container
    1. What is BIMANEXT 0.3 mg/ml single-dose and what is it used for
    2. What you need to know before using BIMANEXT 0.3 mg/ml single-dose
    3. How to use BIMANEXT 0,3 mg/ml single-dose
    4. Possible side effects
    5. How to store BIMANEXT 0.3 mg/ml single-dose
    6. Contents of the pack and other information
  3. BIMANEXT 0,1 mg/ml, eye drops, solution
    1. What is BIMANEXT 0.1 mg/ml and what is it used for
    2. What you need to know before using BIMANEXT 0.1 mg/ml
    3. How to use BIMANEXT 0.1 mg/ml
  4. BIMANEXT must be applied only to the eyes. The recommended dose is one drop of
    1. Possible side effects
    2. How to store BIMANEXT 0.1 mg/ml
    3. Package Contents and Other Information
  5. BIMANEXT 0,1 mg/ml, eye drops, solution, in single-dose container
    1. What is BIMANEXT 0.1 mg/ml single-dose and what is it used for
    2. What you need to know before using BIMANEXT 0.1 mg/ml single dose
    3. How to use BIMANEXT 0.1 mg/ml single dose
    4. Possible side effects
    5. How to store BIMANEXT 0.1 mg/ml single-dose
    6. Contents of the pack and other information

BIMANEXT 0,3 mg/ml, eye drops, solution

Bimatoprost
Generic medicine

Read this leaflet carefully before you start using this medicine as it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others, even if they have the same symptoms as you, as it may be harmful.
  • If you get any side effects, even those not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Contents of this leaflet:

  • 1. What BIMANEXT 0,3 mg/ml is and what it is used for
  • 2. What you need to know before you use BIMANEXT 0,3 mg/ml
  • 3. How to use BIMANEXT 0,3 mg/ml
  • 4. Possible side effects
  • 5. How to store BIMANEXT 0,3 mg/ml
  • 6. Contents of the pack and other information

1. What is BIMANEXT 0.3 mg/ml and what is it used for

BIMANEXT eye drops are an antiglaucoma medication. It belongs to a category of drugs called

prostamides.
BIMANEXT is used to reduce elevated intraocular pressure. This medicine can be used by
alone or together with other eye drops called beta-blockers, which also serve to reduce pressure
in the eye.
The eye contains a clear, aqueous liquid that nourishes its interior. This liquid is
constantly eliminated from the eye and new liquid is produced to replace what has been eliminated. If the
liquid is not eliminated quickly enough, the pressure inside the eye increases.
This medicine helps to increase the amount of liquid that is eliminated, thereby reducing
the pressure inside the eye. Elevated intraocular pressure, if not reduced, can cause
a disease called glaucomaand can eventually cause damage to vision.

2. What you need to know before using BIMANEXT 0.3 mg/ml

Do not use BIMANEXT 0.3 mg/ml

  • if you are allergic to the active ingredient bimatoprost or to any of the other ingredients of this medicine (listed in section 6).
  • if you have had to stop using eye drops in the past due to an undesirable effect caused by the preservative benzalkonium chloride.

Warnings and precautions
Talk to your doctor or pharmacist before using BIMANEXT 0.3 mg/ml.
Consult your doctor if:

  • you suffer from respiratory problems
  • you have liver or kidney problems
  • you have had cataract surgery in the past
  • you suffer from dry eyes
  • you have or have had problems with the cornea (the clear front part of the eye)
  • you wear contact lenses (see “BIMANEXT 0.3 mg/ml contains benzalkonium chloride”)
  • you suffer from or have suffered from hypotension or bradycardia
  • you have had a viral infection or inflammation of the eyes

During treatment, BIMANEXT may cause loss of fat around the eye, which may result in
deepening of the eyelid crease, sunken eye (enophthalmos), drooping of the upper eyelid
(ptosis), tightening of the skin around the eye (dermal calasis involution) and exposure
of the lower white part of the eye (inferior scleral show). The changes are usually mild in degree, but if they are pronounced, they may impair the field of vision. If you stop using
BIMANEXT, the changes may disappear. BIMANEXT may also cause darkening and
lengthening of the eyelashes, and may also darken the eyelids. The color of the iris may also darken. These
changes may be permanent and are more noticeable if only one eye is treated.

Children and adolescents
Bimatoprost has not been tested on patients under 18 years of age and therefore should not be used on
patients under 18 years of age.

Other medicines and BIMANEXT
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any
other medicines.

Pregnancy and breastfeeding
If you are pregnant, suspect you may be pregnant, are planning to become pregnant, or are breastfeeding
with breast milk, ask your doctor or pharmacist for advice before taking this medicine.
BIMANEXT may pass into breast milk, so it is advisable not to breastfeed during treatment with
this medicine.

Driving and operating machinery
After administration of BIMANEXT 0.3 mg/ml, you may experience mild, transient blurred
vision. In this case, do not drive or operate machinery until your vision returns to normal.

BIMANEXT 0.3 mg/ml contains benzalkonium chloride.
BIMANEXT contains a preservative called benzalkonium chloride; it can cause eye irritation and
can discolor soft contact lenses. Avoid contact with soft contact lenses. Do not use the
eye drops while wearing contact lenses. After administering the eye drops, wait 15 minutes before
replacing the contact lenses.

3. How to use BIMANEXT 0.3 mg/ml

Take this medicine following exactly the instructions of your doctor or pharmacist. If you have
doubts, consult your doctor or pharmacist.
BIMANEXT must be applied only to the eyes. The recommended dose is one drop of
BIMANEXT once a day, in the evening, in each eye to be treated.
If you are using BIMANEXT with another ophthalmic medicine, wait at least 5 minutes after using BIMANEXT
before applying the second ophthalmic medicine.
Do not use the medicine more than once a day, as the effectiveness of the treatment may be reduced.

Instructions for use:
Do not use the bottle if the tamper-evident seal on the cap is not intact before first use.

  • 1. Wash your hands. Tilt your head back and look up.
  • 2. Gently lower the lower eyelid to form a small pocket.
  • 3. Invert the bottle and apply gentle pressure to release one drop of eye drops into each eye to be treated.
  • 4. Release the lower eyelid and close your eye for 30 seconds.

Wipe away any excess that runs down your cheek.
If the drop does not enter the eye, repeat the operation.
To avoid infection and injury to the eye, the tip of the bottle must not touch the eye or come into
contact with other surfaces. After using the bottle, close it tightly by screwing the cap back on.

If you use more BIMANEXT 0.3 mg/ml than you should
If you use more BIMANEXT than you should, it is unlikely to cause serious consequences.
Administer the next dose at the usual time. If this causes you concern, consult your doctor or
pharmacist.

If you forget to use BIMANEXT 0.3 mg/ml
If you forget to use BIMANEXT, as soon as you remember, put one drop and then return to
normal administration times. Do not take a double dose to make up for a missed dose.

If you stop using BIMANEXT 0.3 mg/ml
For it to work correctly, BIMANEXT must be used every day. If you stop using BIMANEXT, eye pressure may increase, so you should talk to your doctor before
stopping this treatment.
If you have any doubts about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you get any side effects, even those not listed in this leaflet, tell your doctor or pharmacist.

Very common side effects
These effects may occur in 1 or more patients in 10.
Effects on the eye

  • Longer eyelashes (up to 45% of people)
  • Mild redness (up to 44% of people)
  • Itching (up to 14% of people)

Concerning the eye area

  • Loss of fat in the eye area which may lead to deepening of the eyelid crease, hollowed eye (enophthalmos), drooping of the eyelid (ptosis), tightening of the skin around the eye (dermatocalasis involution) and exposure of the lower white part of the eye (inferior scleral show).

Common side effects
These effects may occur in 1-9 patients in 100.
Effects on the eye

  • Allergic eye reaction
  • Tired eyes
  • Sensitivity to light
  • Darkening of the skin around the eye
  • Darker eyelashes
  • Pain
  • Feeling of something in the eye
  • Sticky eyes
  • Darkening of the iris color
  • Difficulty seeing clearly
  • Irritation
  • Burning
  • Inflamed, red and itchy eyelids
  • Tearing
  • Dryness
  • Worsening of vision
  • Blurred vision
  • Swelling of the clear layer covering the surface of the eye
  • Small ulcers on the surface of the eye, with or without inflammation

Side effects on the body

  • Headache
  • Increase in blood tests of values related to liver function
  • Increased blood pressure values

Uncommon side effects
These effects may occur in 1-9 patients in 1,000.
Concerning the eye

  • Cystoid macular edema (swelling of the retina inside the eye that leads to worsening of vision)
  • Inflammation inside the eye
  • Retinal bleeding
  • Swollen eyelids
  • Eyelid spasms
  • Narrowing of the eyelid, which moves away from the surface of the eye
  • Redness of the skin around the eye

Concerning the body

  • Nausea
  • Dizziness
  • Weakness
  • Hair growth around the eye

Side effects with frequency not known
Concerning the eye

  • Eye discomfort

Concerning the body

  • Asthma
  • Worsening of asthma
  • Worsening of a lung condition called chronic obstructive pulmonary disease (COPD)
  • Shortness of breath
  • Change in skin color (periocular)

Other side effects reported with eye drops containing phosphates
In very rare cases, some patients with severe damage to the clear layer of the front of the eye (the cornea) have developed cloudy areas on the cornea due to calcium accumulation during treatment.

Reporting of side effects
If you get any side effects, even those not listed in this leaflet, tell your doctor or pharmacist. You can also report side effects directly through the national reporting system at www.aifa.gov.it/content/segnalazioni-reazioni-avverse . By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store 0.3 mg/ml

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label of the bottle and on the packaging
after Exp. The expiry date refers to the last day of that month.
After the first opening of the BIMANEXTbottle, use within 28 days; after this period, any
remaining medicine must be disposed of. This will avoid infections. To help you remember, write the date of
first opening in the space provided on the packaging.
Do not dispose of any medicine in wastewater or household waste. Ask your pharmacist how to dispose of
medicines you no longer use. This will help protect the environment.

6. Package contents and other information

What BIMANEXT 0,3 mg/ml contains

  • The active ingredient is bimatoprost. One ml of solution contains 0.3 mg of bimatoprost.
  • The other ingredients are: benzalkonium chloride(preservative), sodium chloride, disodium phosphate

heptahydrate, citric acid monohydrate and water for injections. Small amounts of hydrochloric acid or sodium hydroxide may be added
to maintain a normal acidity level (pH).

Description of the appearance of BIMANEXT 0,3 mg/ml and package contents
BIMANEXT is a clear, colorless eye drop, supplied in a package containing 1 plastic bottle with
a screw cap, containing 3 ml of solution.

Marketing authorization holder
FB Vision S.p.a
Via San Giovanni Scafa, snc

  • 63074 – San Benedetto del Tronto (AP) - Italy

Manufacturer
Genetic S.p.A.
Contrada Canfora
84084 Fisciano (SA)

BIMANEXT 0,3 mg/ml, eye drops, solution in single-dose container

Bimatoprost
Generic medicine

Read this leaflet carefully before using this medicine as it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others, even if they have the same symptoms as you, as it may be harmful.
  • If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Contents of this leaflet:

  • 1. What BIMANEXT 0,3 mg/ml single-dose is and what it is used for
  • 2. What you need to know before you use BIMANEXT 0,3 mg/ml single-dose
  • 3. How to use BIMANEXT 0,3 mg/ml single-dose
  • 4. Possible side effects
  • 5. How to store BIMANEXT 0,3 mg/ml single-dose
  • 6. Contents of the pack and other information

1. What is BIMANEXT 0.3 mg/ml single-dose and what is it used for

BIMANEXT 0.3 mg/ml single-dose is an antiglaucoma drug. It belongs to a category of drugs
called prostamides.
BIMANEXT 0.3 mg/ml eye drops, single-dose solution is used to reduce increased intraocular pressure.
This medicine can be used alone or together with other eye drops called beta-blockers, which
also serve to reduce pressure in the eye.
The eye contains a clear, aqueous liquid that nourishes its interior. This liquid is
constantly eliminated from the eye and new liquid is produced to replace what is eliminated. If the
liquid is not eliminated quickly enough, the pressure inside the eye increases. This medicine serves to increase the amount of liquid that is eliminated, thus reducing
the pressure inside the eye. Elevated intraocular pressure, if not reduced, can cause
a disease called glaucomaand can eventually cause damage to vision.
This medicine does not contain preservatives.

2. What you need to know before using BIMANEXT 0.3 mg/ml single-dose

Do not use this medicine

  • if you are allergic to the active ingredient bimatoprost or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions
Talk to your doctor or pharmacist before using BIMANEXT 0.3 mg/ml single-dose.

Consult your doctor or pharmacist if:

  • you suffer from respiratory problems.
  • you have liver or kidney problems.
  • you have had cataract surgery in the past.
  • you suffer or have suffered from low blood pressure or slowed heartbeat.
  • you have had a viral infection or inflammation of the eyes.

During treatment, BIMANEXT may cause loss of fat around the eye, which may lead to
deepening of the eyelid crease, sunken eye (enophthalmos), drooping of the upper eyelid
(ptosis), tightening of the skin around the eye (dermal calasis involution) and exposure
of the lower white part of the eye (inferior scleral show). The changes are usually mild, but if they are marked, they may impair the visual field. If you stop using
BIMANEXT, the changes may disappear. BIMANEXT 0.3 mg/ml single-dose may also cause
darkening and lengthening of the eyelashes, and may also darken the eyelids. The color of the iris
may also darken. These changes may be permanent and are more noticeable if only one eye is
treated.

Children and adolescents
BIMANEXT 0.3 mg/ml single-dose has not been tested on patients under 18 years of age and therefore should not
be used on patients under 18 years of age.

Other medicines and BIMANEXT 0.3 mg/ml single-dose
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any
other medicines.

Pregnancy and breastfeeding
If you are pregnant, suspect you are pregnant, are planning to become pregnant, or are breastfeeding
ask your doctor or pharmacist for advice before taking this medicine.
BIMANEXT 0.3 mg/ml single-dose may pass into breast milk, so it is advisable not to breastfeed
during treatment with this medicine.

Driving and operating machinery
After administration of BIMANEXT 0.3 mg/ml single-dose, you may experience slight transient
blurred vision. In this case, do not drive or use machinery until your vision returns to
normal.

3. How to use BIMANEXT 0,3 mg/ml single-dose

Take this medicine following exactly the instructions of your doctor or pharmacist. If you have
any doubts, ask your doctor or pharmacist.
The recommended dose is one drop once a day, in the evening, in each eye to be treated. BIMANEXT 0,3
mg/ml single-dose must be applied only to the eyes.
If you are using BIMANEXT 0,3 mg/ml single-dose with another ophthalmic medicine, wait at least 5 minutes after
using BIMANEXT 0,3 mg/ml single-dose before applying the second ophthalmic medicine.
Do not use it more than once a day, as the effectiveness of the treatment may be reduced.

Instructions for use:
Wash your hands before use. Make sure that the single-dose container is intact before use. The
solution must be used immediately after opening. To avoid contamination, be careful
that the open end of the single-dose container does not come into contact with the eye or with other surfaces.

  • 1. Take a single-dose container and hold it in a vertical position (with the cap facing upwards) and unscrew the cap.
  • 2. Gently pull down the lower eyelid to form a pocket. Turn the single-dose container upside down and apply slight pressure to release one drop of eye drops into the eye(s) to be treated. Open and close your eye(s) for a few seconds.
  • 3. Dispose of the single-dose container immediately after use, even if there is some solution left inside.

Dry any excess that runs down your cheek.
If you wear contact lenses, remove them before using this medicine. Wait 15 minutes after
using the eye drops before reinserting the lenses.

If you use more BIMANEXT 0,3 mg/ml single-dose than you should
If you use this medicine more than you should, it is unlikely to cause serious consequences.
Administer the next dose at the usual time. If this causes you concern, consult your doctor or
pharmacist.

If you forget to use BIMANEXT 0,3 mg/ml single-dose
If you forget to use this medicine, as soon as you remember, put one drop and then return to
normal dosing times. Do not take a double dose to make up for a missed dose.

If you stop using BIMANEXT 0,3 mg/ml single-dose
For it to work correctly, BIMANEXT 0,3 mg/ml single-dose must be used every day. If
you stop using BIMANEXT 0,3 mg/ml single-dose, the eye pressure may increase, so you must
talk to your doctor before stopping this treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you get any side effect, including any not listed in this leaflet, tell your doctor or pharmacist.

Very common side effects
These effects may occur in 1 or more patients in 10
Effects on the eye

  • Mild redness (up to 24% of people)

Concerning the eye area

  • Loss of fat in the eye area which may lead to deepening of the eyelid crease, sunken eye (enophthalmos), drooping of the eyelid (ptosis), tightening of the skin around the eye (dermatocalasis involution) and exposure of the lower white part of the eye (inferior scleral show).

Common side effects
These effects may occur in 1-9 patients in 100
Effects on the eye

  • Small ulcers on the surface of the eye, with or without inflammation
  • Irritation
  • Eye itching
  • Pain
  • Dryness
  • Foreign body sensation in the eye
  • Longer eyelashes
  • Darkening of the skin around the eye
  • Reddened eyelids

Uncommon side effects
These effects may occur in 1-9 patients in 1000
Effects on the eye

  • Tired eyes
  • Sensitivity to light
  • Darkening of the iris color
  • Itchy and swollen eyelids
  • Tearing
  • Swelling of the transparent layer covering the surface of the eye
  • Blurred vision

Side effects on the body

  • Headache
  • Growth of hair around the eye

Side effects with frequency not known
Concerning the body

  • Asthma
  • Worsening of asthma
  • Worsening of a lung condition called chronic obstructive pulmonary disease (COPD)
  • Shortness of breath
  • Symptoms of an allergic reaction (swelling, redness of the eye and skin rash)
  • Dizziness
  • Increased blood pressure values
  • Alteration of skin color (around the eye)

Concerning the eye

  • Sticky eyes
  • Eye discomfort

In addition to the side effects of BIMANEXT 0.3 mg/ml single dose, the following side effects have been observed with the multi-dose formulation of BIMANEXT 0.3 mg/ml containing the preservative and may occur in patients taking BIMANEXT 0.3 mg/ml single dose:

  • Burning sensation inside the eye
  • Allergic reaction in the eye
  • Inflamed eyelids
  • Difficulty seeing sharp images
  • Worsening of vision
  • Darkening of eyelashes
  • Retinal bleeding
  • Inflammation inside the eye
  • Cystoid macular edema (swelling of the retina inside the eye leading to worsening of vision)
  • Inflammation of the iris
  • Eyelid spasms
  • Narrowing of the eyelid, which moves away from the surface of the eye
  • Nausea
  • Redness of the skin around the eyes
  • Weakness
  • Increased blood test values related to liver function

Other side effects reported with eye drops containing phosphates
In very rare cases, some patients with severe damage to the transparent layer of the front of the eye (the cornea) have developed opaque areas on the cornea due to calcium accumulation during treatment.

Reporting of side effects
If you get any side effect, including any not listed in this leaflet, tell your doctor or pharmacist. You can also report side effects directly through the national reporting system at www.aifa.gov.it/content/segnalazioni-reazioni-avverse . By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store BIMANEXT 0.3 mg/ml single-dose

Keep this medicine out of the sight and reach of children.
This medicine is for single use only and does not contain preservatives. Do not store unused solution.
After the first opening of the aluminum sachet: use the single-dose containers within 7 days; after this period, any remaining containers must be discarded.
The single-dose container must be used immediately after opening; any remaining medicine must be discarded.
Do not use this medicine after the expiry date which is stated on the single-dose container, on the sachet and on the carton after EXP. The expiry date refers to the last day of that month.
Do not dispose of any medicine in wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. This will help protect the environment.

6. Contents of the pack and other information

What BIMANEXT 0,3 mg/ml single-dose contains

  • The active substance is bimatoprost. One ml of solution contains 0.3 mg of bimatoprost.
  • The other components are: sodium chloride, disodium phosphate heptahydrate, citric acid monohydrate and water for injections. Small amounts of hydrochloric acid or sodium hydroxide may be added to maintain a normal acidity level (pH).

Description of the appearance of BIMANEXT 0,3 mg/ml single-dose and contents of the pack
BIMANEXT 0,3 mg/ml single-dose is a clear, colorless solution, supplied in single-dose plastic containers,
divided into 6 strips of 5 containers each placed in a sachet.
Each single-dose container contains 0.4 ml of solution.
Each pack contains 30 single-dose containers.

Marketing authorisation holder
FB Vision S.p.a
Via San Giovanni Scafa, snc

  • 63074 – San Benedetto del Tronto (AP) - Italy

Manufacturer
Genetic S.p.A.
Contrada Canfora
84084 Fisciano (SA)

Doctor consultation

Nie jesteś pewien, czy ten lek jest odpowiedni dla ciebie?

Omów swoje objawy i leczenie z lekarzem online.

BIMANEXT 0,1 mg/ml, eye drops, solution

Bimatoprost
Generic medicine

Read this leaflet carefully before you start using this medicine, as it contains important
information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others, even if they have the same symptoms as you, as it may be harmful.
  • If you get any side effects, even those not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Contents of this leaflet:

  • 1. What BIMANEXT 0,1 mg/ml is and what it is used for
  • 2. What you need to know before you use BIMANEXT 0,1 mg/ml
  • 3. How to use BIMANEXT 0,1 mg/ml
  • 4. Possible side effects
  • 5. How to store BIMANEXT 0,1 mg/ml
  • 6. Contents of the pack and other information

1. What is BIMANEXT 0.1 mg/ml and what is it used for

BIMANEXT is an antiglaucoma medication. It belongs to a category of drugs called prostamides.
BIMANEXT eye drops are used to reduce elevated intraocular pressure. This medicine can be
used alone or together with other eye drops called beta-blockers, which also serve to reduce
pressure in the eye.
The eye contains a clear, aqueous liquid that nourishes its interior. This liquid is
constantly drained from the eye and new liquid is produced to replace what is drained. If the
liquid is not drained quickly enough, the pressure inside the eye increases. This medicine serves to increase the amount of liquid that is drained, thus reducing
the pressure inside the eye. Elevated intraocular pressure, if not reduced, can cause
a disease called glaucomaand can eventually cause damage to vision.

2. What you need to know before using BIMANEXT 0.1 mg/ml

Do not use BIMANEXT 0.1 mg/ml

  • if you are allergic to the active ingredient bimatoprost or to any of the other ingredients of this medicine

(listed in section 6).

  • if you have had to stop using eye drops in the past due to an undesirable effect caused by the preservative benzalkonium chloride.

Warnings and precautions
Consult your doctor or pharmacist before using BIMANEXT 0.1 mg/ml.
Consult your doctor if:

  • you suffer from respiratory problems
  • you have problems with your liver or kidneys
  • you have had cataract surgery in the past
  • you suffer from dry eyes
  • you have or have had problems with the cornea (the clear front part of the eye)
  • you wear contact lenses (see “BIMANEXT 0.1 mg/ml contains benzalkonium chloride”)
  • you suffer from or have suffered from hypotension or bradycardia
  • you have had a viral infection or inflammation of the eyes.

During treatment, BIMANEXT may cause loss of fat around the eye, which may lead to
deepening of the eyelid crease, sunken eye (enophthalmos), drooping of the upper eyelid
(ptosis), tightening of the skin around the eye (dermatocalasis involution) and exposure
of the lower white part of the eye (inferior scleral show). The changes are usually mild, but if they are pronounced, they may impair the field of vision. If you stop using
BIMANEXT, the changes may disappear. BIMANEXT may also cause darkening and
lengthening of the eyelashes, and may also darken the eyelids. The color of the iris may also darken. These
changes may be permanent and are more noticeable if only one eye is treated.

Children and adolescents
Bimatoprost has not been tested on patients under 18 years of age and therefore should not be used on
patients under 18 years of age.

Other medicines and BIMANEXT
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other
medicines.

Pregnancy and breastfeeding
If you are pregnant, suspect you may be pregnant or are planning a pregnancy, or if you are breastfeeding with
breast milk, ask your doctor or pharmacist for advice before taking this medicine.
BIMANEXT may pass into breast milk, so it is advisable not to breastfeed during treatment with
this medicine.

Driving and operating machinery
After administration of BIMANEXT, you may experience slight transient blurred vision. In
this case, do not drive or operate machinery until your vision returns to normal.

BIMANEXT 0.1 mg/ml contains benzalkonium chloride.
BIMANEXT contains a preservative called benzalkonium chloride; it can cause eye irritation and
can discolor soft contact lenses. Avoid contact with soft contact lenses. Do not use the
eye drops while wearing contact lenses. After administering the eye drops, wait 15 minutes before
reinserting the contact lenses.

3. How to use BIMANEXT 0.1 mg/ml

Take this medicine following exactly the instructions of your doctor or pharmacist. If you have
any doubts, consult your doctor or pharmacist.

BIMANEXT once a day, in the evening, in each eye to be treated.
If you are using BIMANEXT with another ophthalmic medicine, apply BIMANEXT eye drops first and wait 5 minutes
before applying the second ophthalmic medicine.
Do not use the medicine more than once a day, as the effectiveness of the treatment may be reduced.

Instructions for use:
Do not use the bottle if the tamper-evident seal on the cap is not intact before first use.

  • 1. Wash your hands. Tilt your head back and look up.
  • 2. Gently lower the lower eyelid to form a small pocket.
  • 3. Turn the bottle upside down and apply gentle pressure to release one drop of eye drops into each eye to be treated.
  • 4. Release the lower eyelid and close your eye for 30 seconds.

Wipe away any excess that runs down your cheek.
If the drop does not enter the eye, repeat the operation.
To avoid infection and injury to the eye, the tip of the bottle must not touch the eye or come into
contact with other surfaces. After using the bottle, close it tightly by screwing the cap back on.

Use in children and adolescents
BIMANEXT should not be given to children and adolescents under 18 years of age.

If you use more BIMANEXT 0.1 mg/ml than you should
If you use more BIMANEXT than you should, it is unlikely to cause serious consequences.
Administer the next dose at the usual time. If this causes you concern, consult your doctor or
pharmacist.

If you forget to use BIMANEXT 0.1 mg/ml
If you forget to use BIMANEXT, as soon as you remember, put one drop and then return to
normal dosing times. Do not take a double dose to make up for a missed dose.

If you stop using BIMANEXT 0.1 mg/ml
For it to work correctly, BIMANEXT must be used every day. If you stop using BIMANEXT, the eye pressure may increase, so you should talk to your doctor before
stopping this treatment.
If you have any doubts about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any side effects, including those not listed in this leaflet, please tell your doctor or pharmacist.

Very common side effects
These effects may occur in 1 or more patients out of 10.
Effects on the eye

  • Mild redness (up to 29% of people)

Concerning the eye area

  • Loss of fat in the eye area which may lead to deepening of the eyelid crease, sunken eye (enophthalmos), drooping of the eyelid (ptosis), tightening of the skin around the eye (dermatocalasis involution) and exposure of the lower white part of the eye (inferior scleral show).

Common side effects
These effects may occur in 1-9 patients out of 100.
Effects on the eye

  • Small ulcers on the surface of the eye, with or without inflammation
  • Irritation
  • Itchy eyes
  • Lengthening of the eyelashes
  • Irritation when administering eye drops
  • Eye pain

Side effects on the skin

  • Red and itchy eyelids
  • Darkening of the skin around the eye
  • Growth of hair around the eye

Uncommon side effects
These effects may occur in 1-9 patients out of 1,000.
Concerning the eye

  • Darkening of the iris color
  • Tired eyes
  • Swelling of the eye surface
  • Blurred vision
  • Loss of eyelashes

Concerning the skin

  • Dryness
  • Formation of crusts on the edge of the eyelid
  • Swelling of the eyelid
  • Itching

Concerning the body

  • Headache
  • Feeling unwell

Side effects with unknown frequency
Concerning the eye

  • Macular edema (swelling of the retina in the back of the eye which can lead to worsening of vision)
  • Darkening of the eyelids
  • Dry eye
  • Sticky eyes
  • Foreign body sensation in the eye
  • Eye swelling
  • Increased tearing
  • Eye discomfort
  • Sensitivity to light

Concerning the body

  • Asthma
  • Worsening of asthma
  • Worsening of a lung condition called chronic obstructive pulmonary disease (COPD)
  • Shortness of breath
  • Symptoms of an allergic reaction (swelling, redness of the eye and skin rash)
  • Dizziness
  • Increased blood pressure values
  • Alteration of skin color (around the eye)

In addition to the side effects of bimatoprost 0.1 mg/ml, the following side effects have been observed with another medicine containing a
higher concentration of bimatoprost (0.3 mg/ml):

  • Burning sensation in the eye
  • An allergic reaction to the eye
  • Inflamed eyelids
  • Difficulty seeing sharp images
  • Worsening of vision
  • Swelling of the clear layer covering the surface of the eye
  • Tearing
  • Darker eyelashes
  • Retinal bleeding
  • Inflammation inside the eye
  • Cystoid macular edema (swelling of the retina inside the eye leading to worsening of vision)
  • Eyelid spasms
  • Narrowing of the eyelid, which moves away from the surface of the eye
  • Redness of the skin around the eye
  • Weakness
  • Increased values in blood tests related to liver function

Other side effects reported with eye drops containing phosphates
In very rare cases, some patients with severe damage to the clear layer of the front of the eye (the
cornea) have developed opaque areas on the cornea due to calcium accumulation during treatment.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. You can also report side effects directly through the national reporting system at www.aifa.gov.it/content/segnalazioni-reazioni-avverse .
By reporting side effects you can help provide more information on the safety of
this medicine.

5. How to store BIMANEXT 0.1 mg/ml

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label of the vial and on the packaging
after Exp. The expiry date refers to the last day of that month.
After the first opening of the BIMANEXT vial, use within 28 days; after this period, any
remaining medicine must be discarded. This will prevent infections. To help you remember, write the date of
first opening in the space provided on the packaging.
Do not dispose of any medicine in wastewater or household waste. Ask your pharmacist how to dispose of
medicines you no longer use. This will help protect the environment.

6. Package Contents and Other Information

What BIMANEXT 0.1 mg/ml contains

  • The active ingredient is bimatoprost. One ml of solution contains 0.1 mg of bimatoprost.
  • The other components are: benzalkonium chloride(preservative), sodium chloride, disodium phosphate heptahydrate, citric acid monohydrate and water for injections. Small quantities of hydrochloric acid or sodium hydroxide may be added to maintain a normal acidity level (pH).

Description of the appearance of BIMANEXT 0.1 mg/ml and package contents
BIMANEXT is a clear, colorless eye drop, supplied in a package containing 1 plastic bottle with
a screw cap containing 3 ml of solution.

Marketing Authorization Holder
FB Vision S.p.a
Via San Giovanni Scafa, snc

  • 63074 – San Benedetto del Tronto (AP) - Italy

Manufacturer
Genetic S.p.A.
Contrada Canfora
84084 Fisciano (SA)

Medicine questions

Zacząłeś przyjmować lek i masz pytania?

Omów swoje objawy i leczenie z lekarzem online.

BIMANEXT 0,1 mg/ml, eye drops, solution, in single-dose container

Bimatoprost

Read this leaflet carefully before you start using this medicine, as it contains important
information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others, even if they have the same symptoms as you, as it may be harmful.
  • If you get any side effects, even those not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Contents of this leaflet:

  • 1. What BIMANEXT 0,1 mg/ml single-dose is and what it is used for
  • 2. What you need to know before you use BIMANEXT 0,1 mg/ml single-dose
  • 3. How to use BIMANEXT 0,1 mg/ml single-dose
  • 4. Possible side effects
  • 5. How to store BIMANEXT 0,1 mg/ml single-dose
  • 6. Contents of the pack and other information

1. What is BIMANEXT 0.1 mg/ml single-dose and what is it used for

BIMANEXT 0.1 mg/ml single-dose is an antiglaucoma drug. It belongs to a category of drugs
called prostamides.
BIMANEXT 0.1 mg/ml eye drops solution single-dose is used to reduce high eye pressure.
This medicine can be used alone or together with other eye drops called beta-blockers, which
also serve to reduce pressure in the eye.
The eye contains a clear, aqueous liquid that nourishes its interior. This liquid is
constantly drained from the eye and new liquid is produced to replace what is drained. If the
liquid is not drained quickly enough, the pressure inside the eye increases. This medicine helps to increase the amount of liquid that is drained, thus reducing
the pressure inside the eye. High eye pressure, if not reduced, can cause
a disease called glaucomaand can eventually cause damage to vision.
This medicine does not contain preservatives.

2. What you need to know before using BIMANEXT 0.1 mg/ml single dose

Do not use this medicine

  • if you are allergic to the active ingredient bimatoprost or to any of the other ingredients of this medicine

(listed in section 6).

Warnings and precautions
Consult your doctor or pharmacist before using BIMANEXT 0.1 mg/ml single dose.

Consult your doctor or pharmacist if:

  • you suffer from respiratory problems
  • you have liver or kidney problems
  • you have had cataract surgery in the past
  • you suffer from dry eyes
  • you have or have had problems with the cornea (the clear front part of the eye)
  • you suffer or have suffered from hypotension or bradycardia
  • you have had a viral infection or inflammation of the eyes.

During treatment, BIMANEXT may cause loss of fat around the eye, which may lead to
deepening of the eyelid crease, sunken eye (enophthalmos), drooping of the upper eyelid
(ptosis), tightening of the skin around the eye (dermal calasis involution) and exposure
of the lower white part of the eye (inferior scleral show). The changes are usually mild in degree,
but if they are pronounced, they may impair the field of vision. If you stop using
BIMANEXT, the changes may disappear. BIMANEXT 0.1 mg/ml single dose may also cause
darkening and lengthening of the eyelashes, and may also darken the eyelids. The color of the iris
may also darken. These changes may be permanent and are more noticeable if only one eye is
treated.

Children and adolescents
BIMANEXT 0.1 mg/ml single dose has not been tested on patients under 18 years of age and therefore should not
be used in patients under 18 years of age.

Other medicines and BIMANEXT 0.1 mg/ml single dose
Tell your doctor or pharmacist if you are taking, have recently taken or might take any
other medicines.

Pregnancy and breastfeeding
If you are pregnant, suspect you are pregnant or are planning to become pregnant, or if you are breastfeeding
with breast milk, ask your doctor or pharmacist for advice before taking this medicine.
BIMANEXT 0.1 mg/ml single dose may pass into breast milk, so it is advisable not to breastfeed
during treatment with this medicine.

Driving and operating machinery
After administration of BIMANEXT 0.1 mg/ml single dose, you may experience mild, transient
blurred vision. In this case, do not drive or operate machinery until your vision returns to
normal.

3. How to use BIMANEXT 0.1 mg/ml single dose

Take this medicine following exactly the instructions of your doctor or pharmacist. If you have
any doubts, ask your doctor or pharmacist.
BIMANEXT 0.1 mg/ml single dose must be applied only to the eyes. The recommended dose is one
drop once a day, in the evening, in each eye to be treated.
If you use BIMANEXT 0.1 mg/ml single dose with another ophthalmic medicine, apply BIMANEXT
eye drops first and wait 5 minutes before applying the second ophthalmic medicine.
Do not use the medicine more than once a day, as the effectiveness of the treatment may be reduced.

Instructions for use:
Wash your hands before use. Make sure that the single dose container is intact before use. The
solution must be used immediately after opening. To avoid contamination, be careful
that the open end of the single dose container does not come into contact with the eye or with other surfaces.

  • 1. Take a single dose container and hold it in a vertical position (with the cap facing upwards) and rotate the cap.
  • 2. Gently lower the lower eyelid to form a pocket. Turn the single dose container upside down and apply slight pressure to release one drop of eye drops into the/into the eye(s) to be treated. Open and close your eye/eyes for a few seconds.
  • 3. Discard the single dose container immediately after use, even if there is some solution remaining inside.

Dry any excess that runs down your cheek.
If you wear contact lenses, remove them before using this medicine. Wait 15 minutes after
using the eye drops before reinserting the lenses.

Use in children and adolescents
BIMANEXT 0.1 mg/ml single dose should not be given to children and adolescents under 18 years of
age.

If you use more BIMANEXT 0.1 mg/ml single dose than you should
If you use more of this medicine than you should, it is unlikely to cause serious consequences.
Administer the next dose at the usual time. If this causes you concern, consult your doctor or
pharmacist.

If you forget to use BIMANEXT 0.1 mg/ml single dose
If you forget to use this medicine, as soon as you remember, put one drop and then return to
normal administration times. Do not take a double dose to make up for a missed dose.

If you stop using BIMANEXT 0.1 mg/ml single dose
For it to work correctly, BIMANEXT 0.1 mg/ml single dose must be used every day. If
you stop using BIMANEXT 0.1 mg/ml single dose, the eye pressure may increase, so you must
talk to your doctor before stopping this treatment.
If you have any doubts about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you get any side effects, even those not listed in this leaflet, tell your doctor or pharmacist.

Very common side effects
These effects may occur in 1 or more patients in 10.
Effects on the eye

  • Mild redness (up to 29% of people)

Concerning the eye area

  • Loss of fat in the eye area which may lead to deepening of the eyelid crease, sunken eye (enophthalmos), drooping of the eyelid (ptosis), tightening of the skin around the eye (dermatocalasis involution) and exposure of the lower white part of the eye (inferior scleral show).

Common side effects
These effects may occur in 1-9 patients in 100.
Effects on the eye

  • Small ulcers on the surface of the eye, with or without inflammation
  • Irritation
  • Itchy eyes
  • Lengthening of eyelashes
  • Irritation when administering eye drops
  • Eye pain

Side effects on the skin

  • Red and itchy eyelids
  • Darkening of the skin around the eye
  • Growth of hairs around the eye

Uncommon side effects
These effects may occur in 1-9 patients in 1,000.
Concerning the eye

  • Darkening of the color of the iris
  • Tired eyes
  • Swelling of the surface of the eye
  • Blurred vision
  • Loss of eyelashes

Concerning the skin

  • Dryness
  • Formation of crusts on the edge of the eyelid
  • Swelling of the eyelid
  • Itching

Concerning the body

  • Headache
  • Feeling unwell

Side effects with unknown frequency
Concerning the eye

  • Macular edema (swelling of the retina in the back of the eye which may lead to worsening of vision)
  • Darkening of the eyelids
  • Dry eye
  • Sticky eyes
  • Feeling of a foreign body in the eye
  • Swelling of the eye
  • Increased tearing
  • Eye discomfort
  • Sensitivity to light

Concerning the body

  • Asthma
  • Worsening of asthma
  • Worsening of a lung condition called chronic obstructive pulmonary disease (COPD)
  • Shortness of breath
  • Symptoms of an allergic reaction (swelling, redness of the eye and skin rash)
  • Dizziness
  • Increased blood pressure values
  • Alteration of skin color (around the eye)

In addition to the side effects of bimatoprost 0.1 mg/ml, the following side effects have been observed with another medicine containing a
higher concentration of bimatoprost (0.3 mg/ml):

  • Burning sensation in the eye
  • An allergic reaction to the eye
  • Inflamed eyelids
  • Difficulty seeing clear images
  • Worsening of vision
  • Swelling of the clear layer covering the surface of the eye
  • Tearing
  • Darker eyelashes
  • Retinal bleeding
  • Inflammation inside the eye
  • Cystoid macular edema (swelling of the retina inside the eye that leads to worsening of vision)
  • Eyelid spasms
  • Narrowing of the eyelid, which moves away from the surface of the eye
  • Redness of the skin around the eye
  • Weakness
  • Increase in blood test values related to liver function

Other side effects reported with eye drops containing phosphates
In very rare cases, some patients with severe damage to the clear layer of the front of the eye (the
cornea) have developed opaque areas on the cornea due to calcium accumulation during treatment.

Reporting of side effects
If you get any side effects, even those not listed in this leaflet, tell your
doctor or pharmacist. You can also report side effects directly through the national reporting system at www.aifa.gov.it/content/segnalazioni-reazioni-avverse .
By reporting side effects you can help provide more information on the safety of
this medicine.

5. How to store BIMANEXT 0.1 mg/ml single-dose

Keep this medicine out of the sight and reach of children.
Store in the original packaging to protect the medicine from light.
This medicine is for single use only and does not contain preservatives. Do not store unused solution.
After the first opening of the aluminium sachet: use the single-dose containers within 7 days; after this period, any remaining containers must be discarded.
The single-dose container must be used immediately after opening; any remaining medicine must be discarded.
Do not use this medicine after the expiry date which is stated on the single-dose container, on the sachet and on the carton after Exp. The expiry date refers to the last day of that month.
Do not dispose of any medicine in wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. This will help protect the environment.

6. Contents of the pack and other information

What BIMANEXT 0,1 mg/ml single-dose contains

  • The active ingredient is bimatoprost. One ml of solution contains 0.1 mg of bimatoprost.
  • The other components are: sodium chloride, disodium phosphate heptahydrate, citric acid monohydrate and water for injections. Small amounts of hydrochloric acid or sodium hydroxide may be added to maintain a normal acidity level (pH).

Description of the appearance of BIMANEXT 0,1 mg/ml single-dose and contents of the pack
BIMANEXT 0,1 mg/ml single-dose is a clear and colourless solution, supplied in a pack containing
30 single-dose containers of 0.15 ml.

Marketing Authorisation Holder
FB Vision S.p.a
Via San Giovanni Scafa, snc

  • 63074 – San Benedetto del Tronto (AP) - Italy

Manufacturer
Genetic S.p.A.
Contrada Canfora
84084 Fisciano (SA)

  • BIMANEXT
  • Kraj rejestracji
  • Postać farmaceutyczna
    Eye drops, solution, 0.1 MG/ML
  • Kod ATC
    S01EE03
  • Substancja czynna
  • Wymaga recepty
    Tak
  • Producent
  • Zamienniki BIMANEXT
    Postać farmaceutyczna: Eye drops, solution, 0.3 MG/ML
    Substancja czynna: bimatoprost
    Producent: SIFI S.P.A.
    Wymaga recepty
    Postać farmaceutyczna: Eye drops, solution, 0.1 MG/ML
    Substancja czynna: bimatoprost
    Producent: GENETIC S.P.A.
    Wymaga recepty
    Postać farmaceutyczna: Eye drops, solution, 0.1 MG/ML
    Substancja czynna: bimatoprost
    Producent: DOC GENERICI SRL
    Wymaga recepty

Odpowiedniki BIMANEXT w innych krajach

Leki z tą samą substancją czynną dostępne w innych krajach.

Odpowiednik BIMANEXT w Hiszpania

Postać farmaceutyczna: KROPLE DO OCZU, 0,1 mg/ml
Substancja czynna: bimatoprost
Producent: Visufarma S.P.A.
Wymaga recepty
Postać farmaceutyczna: ŻEL DO OCZU, 0.1 mg/g
Substancja czynna: bimatoprost
Producent: Laboratoires Thea
Wymaga recepty
Postać farmaceutyczna: KROPLE DO OCZU, 0,3 mg/ml
Substancja czynna: bimatoprost
Wymaga recepty
Postać farmaceutyczna: KROPLE DO OCZU, 0.3 mg/ml
Substancja czynna: bimatoprost
Wymaga recepty
Postać farmaceutyczna: KROPLE DO OCZU, 0.3 mg/mL
Substancja czynna: bimatoprost
Wymaga recepty
Postać farmaceutyczna: KROPLE DO OCZU, 0,3 mg/ml
Substancja czynna: bimatoprost
Wymaga recepty

Odpowiednik BIMANEXT w Polska

Postać farmaceutyczna: Żel, 0,1 mg/g
Substancja czynna: bimatoprost
Wymaga recepty
Postać farmaceutyczna: Krople, 0,3 mg/ml
Substancja czynna: bimatoprost
Wymaga recepty
Postać farmaceutyczna: Krople, 0,3 mg/ml
Substancja czynna: bimatoprost
Producent: Rafarm S.A.
Wymaga recepty
Postać farmaceutyczna: Krople, 0,3 mg/ml
Substancja czynna: bimatoprost
Importer: Rompharm Company SRL Zakłady Farmaceutyczne POLPHARMA S.A.
Wymaga recepty

Odpowiednik BIMANEXT w Ukraina

Postać farmaceutyczna: drops, 0.3 mg/ml, 3 ml
Substancja czynna: bimatoprost
Postać farmaceutyczna: drops, 0.1 mg/ml; 3 ml in a dropper bottle
Substancja czynna: bimatoprost
Wymaga recepty
Postać farmaceutyczna: drops, 0.3 mg/ml; 3 ml in vials
Substancja czynna: bimatoprost
Wymaga recepty
Postać farmaceutyczna: drops, 0.3 mg/ml, 3 ml
Substancja czynna: bimatoprost
Producent: Rafarm S.A.
Wymaga recepty
Postać farmaceutyczna: drops, 0.3 mg/ml in 3 ml dropper bottle
Substancja czynna: bimatoprost
Postać farmaceutyczna: drops, 0.03%; 2.5 ml; 5 ml; 7.5 ml
Substancja czynna: bimatoprost
Producent: Mikro Labs Limited
Wymaga recepty

Lekarze online w sprawie BIMANEXT

Omów stosowanie BIMANEXT, bezpieczeństwo i ocenę zasadności recepty zgodnie z obowiązującymi przepisami.

Lekarz
5.0(36)

Andrei Popov

Medycyna ogólnaMedycyna bólu7 lat doświadczenia

Dr Andrei Popov jest lekarzem rodzinnym ze specjalistycznym przygotowaniem w zakresie leczenia bólu przewlekłego. Prowadzi konsultacje wideo dla dorosłych w Hiszpanii i w całej Europie: zarówno jeśli od miesięcy zmagasz się z bólem, którego nikt nie potrafił dobrze wyjaśnić, jak i wtedy, gdy potrzebujesz rozwiązać problem zdrowotny bez czekania tygodniami na wizytę.

Jego podejście jest jasne: wysłuchać, uporządkować Twój przypadek i przedstawić praktyczny plan działania oparty na medycynie opartej na dowodach oraz dostosowany do Twojej historii medycznej i potrzeb.

Ból: w czym może pomóc

  •   Ból przewlekły (ponad 3 miesiące)
  •   Migrena i nawracające lub bardzo silne bóle głowy
  •   Ból szyi, odcinka lędźwiowego, pleców i stawów
  •   Ból pourazowy po urazach lub operacjach
  •   Ból pochodzenia neurologicznego: neuralgia, ból neuropatyczny, fibromialgia

Medycyna ogólna

  •   Częste infekcje dróg oddechowych (przeziębienie, grypa, uporczywy kaszel)
  •   Nadciśnienie, cukrzyca i zaburzenia metaboliczne
  •   Omówienie wyników badań laboratoryjnych oraz raportów MRI/CT (wyjaśnione prostym językiem)
  •   Medycyna profilaktyczna i monitorowanie zdrowia
  •   Druga opinia oraz dostosowanie leczenia (jeśli jest to klinicznie uzasadnione)

Jak wygląda konsultacja
 Każda sesja trwa do 30 minut. Omawiane są objawy, historia choroby, przyjmowane leki oraz dostarczone badania. Na zakończenie otrzymujesz jasny plan leczenia, kolejne kroki oraz wskazówki, kiedy warto zaplanować dalszą kontrolę. Jeśli zostaną wykryte sygnały alarmowe, lekarz jasno poinformuje, czy konieczna jest wizyta osobista lub pilna pomoc medyczna.

Umów wideokonsultację
zł365
Lekarz
5.0(19)

Nuno Tavares Lopes

Medycyna rodzinnaMedycyna ogólna18 lat doświadczenia

Lek. Nuno Tavares Lopes jest licencjonowanym lekarzem w Portugalii z 17-letnim doświadczeniem w medycynie ratunkowej, medycynie rodzinnej, praktyce ogólnej i zdrowiu publicznym. Pełni funkcję Dyrektora ds. Medycznych i Zdrowia Publicznego w międzynarodowej sieci medycznej oraz jest zewnętrznym konsultantem WHO i ECDC.

Zakres konsultacji obejmuje:

  • Opiekę doraźną: infekcje, gorączka, ból w klatce piersiowej lub brzuchu, drobne urazy, nagłe przypadki pediatryczne
  • Medycynę rodzinną: nadciśnienie, cukrzyca, wysoki cholesterol, opieka nad chorobami przewlekłymi
  • Medycynę podróży: porady przedwyjazdowe, szczepienia, zaświadczenia fit-to-fly, choroby związane z podróżą
  • Zdrowie seksualne i reprodukcyjne: PrEP, profilaktyka STD, konsultacje, leczenie
  • Kontrolę masy ciała i zdrowy styl życia: indywidualne programy odchudzania, porady dotyczące stylu życia
  • Problemy dermatologiczne i laryngologiczne: trądzik, egzema, alergie, wysypki, ból gardła, zapalenie zatok
  • Leczenie bólu: ból ostry i przewlekły, opieka pooperacyjna
  • Zdrowie publiczne: profilaktyka, badania przesiewowe, monitorowanie długoterminowe
  • Zwolnienia lekarskie (Baixa médica) powiązane z Segurança Social w Portugalii
  • Zaświadczenia medyczne IMT potrzebne do wymiany prawa jazdy
Lek. Nuno Tavares Lopes zapewnia opiekę medyczną pacjentom stosującym leki z grupy GLP-1 (Mounjaro, Wegovy, Ozempic, Rybelsus) w ramach leczenia nadwagi lub otyłości. Oferuje indywidualny plan terapii, regularne wizyty kontrolne, dostosowanie dawek oraz zalecenia dotyczące łączenia leczenia z trwałymi zmianami stylu życia. Konsultacje odbywają się zgodnie z europejskimi standardami medycznymi.

Lek. Lopes zajmuje się również interpretacją badań diagnostycznych, opieką nad pacjentami złożonymi oraz zapewnia wsparcie wielojęzyczne. Niezależnie od tego, czy chodzi o nagłe problemy zdrowotne, czy długoterminową opiekę, pomaga pacjentom działać z pewnością i spokojem.

Umów wideokonsultację
zł297
Lekarz
0.0(0)

Antonio Cayatte

Medycyna ogólna44 lat doświadczenia

Dr Antonio Cayatte to lekarz medycyny ogólnej i ostrej z ponad 30-letnim doświadczeniem klinicznym, naukowym i dydaktycznym. Prowadzi konsultacje online dla dorosłych pacjentów z ostrymi objawami lub chorobami przewlekłymi, wymagającymi kompleksowej opieki. Najczęstsze powody konsultacji: 

  • nagłe lub niejasne objawy wymagające szybkiej oceny
  • kontrola i leczenie chorób przewlekłych
  • opieka po hospitalizacji i analiza wyników badań
  • wsparcie medyczne podczas pobytu za granicą

Ukończył studia medyczne na Uniwersytecie Lizbońskim, przez wiele lat wykładał medycynę wewnętrzną na Boston University School of Medicine. Posiada aktywne prawo do wykonywania zawodu lekarza w Portugalii i Wielkiej Brytanii. Jest członkiem American Heart Association. Konsultacje odbywają się w języku angielskim lub portugalskim. Pacjenci cenią jego doświadczenie, rzeczowość i indywidualne podejście do każdej sytuacji.

Dr Antonio Cayatte zapewnia kompleksową opiekę w szerokim zakresie powszechnych problemów zdrowotnych, w tym:

  • Układ oddechowy i laryngologia: ostre zapalenie oskrzeli, stany związane z zapaleniem płuc, zapalenie zatok, zapalenie migdałków, infekcje ucha, choroby gardła, alergiczny nieżyt nosa
  •  Zdrowie oczu: alergiczne i infekcyjne zapalenie spojówek, a także zaczerwienione lub podrażnione oczy
  •  Układ pokarmowy i moczowy: choroba refluksowa przełyku (GERD), zapalenie żołądka, zakażenia dróg moczowych, zapalenie pęcherza
  •  Choroby przewlekłe: nadciśnienie tętnicze, podwyższony cholesterol oraz uporządkowane planowanie kontroli masy ciała
Umów wideokonsultację
zł323
Lekarz
0.0(0)

Hocine Lokchiri

Medycyna ogólna21 lata doświadczenia

Lek. Hocine Lokchiri to francuski konsultant z ponad 20-letnim doświadczeniem w medycynie ogólnej i ratunkowej. Przyjmuje osoby dorosłe i dzieci, pomagając w nagłych objawach, infekcjach, nagłym pogorszeniu samopoczucia oraz w typowych sytuacjach, które wymagają szybkiej oceny lekarskiej. Pracował we Francji, Szwajcarii i Zjednoczonych Emiratach Arabskich, dzięki czemu swobodnie porusza się w różnych systemach ochrony zdrowia i potrafi skutecznie prowadzić pacjentów w szerokim zakresie schorzeń. Pacjenci cenią go za spokojny styl pracy, jasne wyjaśnienia i podejście oparte na aktualnych dowodach medycznych.

Konsultacja online z lekarzem jest odpowiednia wtedy, gdy potrzebna jest szybka ocena objawów, wskazówki dotyczące dalszego postępowania lub wyjaśnienie, czy konieczna jest wizyta stacjonarna. Do najczęstszych powodów zgłaszania się należą:

  • gorączka, dreszcze, uczucie osłabienia
  • kaszel, ból gardła, katar lub łagodna duszność
  • zapalenie oskrzeli oraz łagodne zaostrzenia astmy
  • nudności, biegunka, ból brzucha, objawy infekcji jelitowej
  • wysypki, reakcje alergiczne, zaczerwienienia, ukąszenia
  • bóle mięśni i stawów, lekkie urazy, skręcenia
  • bóle głowy, zawroty, objawy migreny
  • problemy ze snem oraz dolegliwości związane ze stresem
  • omówienie wyników badań i planu leczenia
  • kontrola chorób przewlekłych w stabilnej fazie
Pacjenci często kontaktują się z lek. Lokchirim, gdy objawy pojawiają się nagle i budzą niepokój, gdy dziecko zaczyna źle się czuć bez wyraźnej przyczyny, gdy wysypka zmienia wygląd lub szybko się rozszerza, lub gdy trzeba podjąć decyzję, czy konieczny jest kontakt osobisty. Jego duże doświadczenie w medycynie ratunkowej jest szczególnie cenne podczas konsultacji online — pomaga ocenić ryzyko, wskazać objawy alarmowe i zaplanować kolejne bezpieczne kroki.

Są też sytuacje, których nie da się bezpiecznie prowadzić online. Utrata przytomności, silny ból w klatce piersiowej, drgawki, masywne krwawienie, poważne urazy lub objawy sugerujące udar czy zawał wymagają natychmiastowego wezwania lokalnych służb ratunkowych. Takie zasady zwiększają bezpieczeństwo i budują zaufanie pacjentów.

Zaawansowane szkolenia lek. Lokchiriego obejmują:

  • Advanced Trauma Life Support (ATLS)
  • BLS/ACLS – podstawowe i zaawansowane wsparcie krążeniowo-oddechowe
  • PALS – zaawansowane wsparcie życia u dzieci
  • PHTLS – przedszpitalna opieka nad pacjentem pourazowym
  • eFAST i echokardiografia przezklatkowa w stanach nagłych
  • medycyna lotnicza
Jest aktywnym członkiem kilku organizacji zawodowych, m.in. Francuskiego Towarzystwa Medycyny Ratunkowej (SFMU), Francuskiego Stowarzyszenia Lekarzy Medycyny Ratunkowej (AMUF) oraz Szwajcarskiego Towarzystwa Medycyny Ratunkowej i Ratownictwa (SGNOR). W pracy stawia na jasną komunikację, precyzyjną ocenę objawów i wspólne podejmowanie decyzji z pacjentem.
Umów wideokonsultację
zł272
Lekarz
0.0(0)

Muhammad Tayyab Altaf

Medycyna ogólna3 lat doświadczenia

Lek. Muhammad Tayyab Altaf to lekarz podstawowej opieki zdrowotnej z szerokim międzynarodowym doświadczeniem klinicznym, oferujący konsultacje online dla dorosłych i dzieci. Pracował we Włoszech, Stanach Zjednoczonych oraz w innych środowiskach medycznych, co pozwala mu skutecznie prowadzić zarówno pacjentów z nagłymi objawami, jak i osoby z chorobami przewlekłymi.

Jego doświadczenie obejmuje leczenie chorób wieloukładowych, profilaktykę, długoterminowe prowadzenie pacjentów oraz wsparcie osób z bardziej złożonymi problemami zdrowotnymi. Lekarz łączy praktykę kliniczną z działalnością naukową w dziedzinach medycznych i chirurgicznych, co pozwala na precyzyjną ocenę stanu zdrowia, trafną diagnostykę oraz tworzenie uporządkowanych, opartych na dowodach planów leczenia. Pacjenci cenią go za spokojną komunikację, jasne wyjaśnienia i pomoc w podejmowaniu świadomych decyzji.

Konsultacja online z lek. Altafem jest odpowiednia w wielu sytuacjach, kiedy potrzebna jest szybka opinia lekarska lub wyznaczenie bezpiecznego dalszego kroku. Lekarz zajmuje się problemami zdrowotnymi dotyczącymi układów: sercowo-naczyniowego, oddechowego, pokarmowego, neurologicznego, hematologicznego i endokrynologicznego. Do częstych powodów kontaktu należą:

  • nadciśnienie i inne zaburzenia ciśnienia tętniczego
  • choroba niedokrwienna serca i dławica piersiowa
  • astma, POChP i rozedma płuc
  • zapalenie płuc i włóknienie płuc
  • gastroenteritis i infekcje układu pokarmowego
  • choroby wątroby, również związane z alkoholem
  • padaczka, napady drgawkowe i następstwa udaru
  • demencja i zaburzenia funkcji poznawczych
  • niedokrwistość i inne zmiany hematologiczne
  • cukrzyca, choroby tarczycy i zaburzenia przysadki
Pacjenci zgłaszają się do niego z nowymi lub nasilającymi się objawami, wahaniami ciśnienia, łagodnym bólem w klatce piersiowej, dusznością, problemami trawiennymi, podejrzeniem infekcji, przewlekłym zmęczeniem lub dolegliwościami wpływającymi na codzienne funkcjonowanie. Lekarz pomaga także w interpretacji wyników badań, modyfikacji terapii i planowaniu długoterminowego postępowania.

Jego doświadczenie zawodowe obejmuje praktykę kliniczną w szpitalu Policlinico San Matteo w Pawii (Włochy), Mount Sinai Hospital w Nowym Jorku (Stany Zjednoczone) oraz w innych placówkach ochrony zdrowia, co pozwala mu z pewnością i przejrzystością prowadzić leczenie szerokiego zakresu schorzeń ostrych i przewlekłych.

W sytuacjach medycznie uzasadnionych lek. Altaf może wystawić zaświadczenia o stanie zdrowia i zdolności do aktywności fizycznej, w tym dokumenty potrzebne do zajęć sportowych, siłowni lub zwiększonego wysiłku fizycznego – zgodnie ze stanem zdrowia pacjenta.

Niektóre stany nie nadają się do konsultacji online. Utrata przytomności, silny ból w klatce, masywne krwawienie, napady drgawkowe, poważne urazy oraz objawy sugerujące udar lub zawał wymagają natychmiastowej pomocy w lokalnych oddziałach ratunkowych. Lekarz zawsze kieruje się bezpieczeństwem pacjenta.

W swojej pracy lek. Muhammad Tayyab Altaf stawia na jasną komunikację, precyzyjne decyzje i wspólne ustalanie kolejnych kroków. Dzięki temu pacjenci otrzymują wsparcie, rzetelną ocenę stanu zdrowia i bezpieczne wskazówki – niezależnie od miejsca, w którym się znajdują.

Umów wideokonsultację
zł238

Uzyskaj receptę na BIMANEXT online

1

Wypełnij 2-minutowy formularz

Opisz swoje objawy, historię choroby i lek, o który prosisz.

2

Wybierz lekarza lub pozwól nam przydzielić

Wybierz specjalistę lub dopasujemy Cię do najbliższego dostępnego lekarza.

3

Lekarz analizuje Twój przypadek

Zazwyczaj w ciągu 30 minut. Może zadawać dodatkowe pytania przez czat.

4

Odbierz w dowolnej aptece

Recepta elektroniczna wysłana na Twój e-mail — ważna w całej Polsce.

Często zadawane pytania

Czy BIMANEXT wymaga recepty?

BIMANEXT wymaga recepty w Włochy. Możesz skonsultować się z lekarzem online, aby sprawdzić, czy ten lek może być odpowiedni w Twojej sytuacji.

Jaka jest substancja czynna w BIMANEXT?

Substancją czynną w BIMANEXT jest bimatoprost. Informacja ta pomaga rozpoznać leki o tym samym składzie, ale pod różnymi nazwami handlowymi.

Kto produkuje BIMANEXT?

BIMANEXT jest produkowany przez FB VISION SPA. Nazwy handlowe i opakowania mogą się różnić w zależności od dystrybutora.

Którzy lekarze mogą ocenić stosowanie BIMANEXT online?

Lekarze, tacy jak Lekarze rodzinni, Psychiatrzy, Dermatolodzy, Kardiolodzy, Endokrynolodzy, Gastroenterolodzy, Pulmonolodzy, Nefrolodzy, Reumatolodzy, Hematolodzy, Zakaźnicy, Alergolodzy, Geriatrzy, Pediatrzy, Onkolodzy, mogą ocenić, czy stosowanie BIMANEXT jest odpowiednie w Twoim przypadku, w zależności od sytuacji klinicznej i lokalnych przepisów. Możesz umówić konsultację online, aby omówić objawy i możliwe dalsze kroki.

Jak kupić BIMANEXT w Polsce?

Polska posiada dobrze rozwiniętą infrastrukturę ochrony zdrowia w dużych miastach, takich jak Warszawa, Kraków, Wrocław i Gdańsk. Apteki są łatwo dostępne i działają zgodnie z obowiązującymi przepisami, zapewniając dostęp do leków na receptę.

Możesz kupić BIMANEXT w Warszawie, Krakowie, Wrocławiu lub Gdańsku w każdej aptece, posiadając ważną receptę.

Aby uzyskać receptę, możesz skorzystać z Oladoctor:

Jakie są alternatywy dla BIMANEXT?

Inne leki zawierające tę samą substancję czynną (bimatoprost) to m.in. AMIRIOX, BIALVITS, BIMADOK. Mogą one różnić się nazwą handlową lub postacią, ale zawierają ten sam składnik terapeutyczny. Przed zmianą lub rozpoczęciem nowego leku skonsultuj się z lekarzem.

Bądź na bieżąco z Oladoctor

Informacje o nowych usługach, aktualizacjach produktu i przydatnych materiałach dla pacjentów.